Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P20062
UPID:
TCO2_HUMAN
Alternative names:
Transcobalamin II
Alternative UPACC:
P20062; Q96FD4; Q9BVI8; Q9UCI5; Q9UCI6; Q9UDM0
Background:
Transcobalamin-2, also known as Transcobalamin II, is the primary vitamin B12-binding and transport protein. It plays a crucial role in delivering cobalamin to cells, essential for DNA synthesis and neurological function.
Therapeutic significance:
Transcobalamin II deficiency leads to various forms of anemia, highlighting the protein's critical role in human health. Targeting Transcobalamin-2 pathways could offer new avenues for treating cobalamin-related disorders.